New England Journal of Medicine· 2017Q1

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis et al.

5,956citations
Q1SCImago
2017year

Short summary

Axicabtagene ciloleucel (axi-cel) CAR T-cell therapy achieved an 82% objective response rate, including a 54% complete response rate, in patients with refractory large B-cell lymphoma.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Oncology

OncologyMedicine